A capital and private equity investor with a flexible investment mandate invests across a wide range of stages and sectors. On the venture capital side, the firm typically participates in Seed through Series B financings and is open to both leading and co-investing. Investments are generally made through special purpose vehicles, with typical allocation sizes ranging from approximately $2M to $20M. The firm primarily focuses on opportunities within the United States.
Within healthcare and life sciences, the firm invests in therapeutics, medical devices, digital health, and diagnostics. For therapeutics, the firm prefers opportunities that are approaching clinical development or already in clinical trials. Within medical devices, the firm focuses on technologies that are nearing regulatory approval or have already obtained clearance or approval. The firm is disease-agnostic and evaluates opportunities based on the strength of the technology, clinical potential, and commercial opportunity.
From a company and management team perspective, the firm generally prefers board representation and seeks to work closely with portfolio companies to support strategic growth and value creation.
If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com.
Next Phase Newsletter 
Leave a comment